Tetradecyl hydrogen sulfate (ester) is an anionic surfactant used to treat small uncomplicated varicose veins. Sodium tetradecyl sulfate has been widely used since the 1950s, and in 1978 the first successful report of injecting a 1% solution into spider angiomas in 144 patients was made.
- Mechanism
- Curator reviewed · 3 references
When injected directly into a vein, sodium tetradecyl sulfate causes intimal inflammation and venous thrombus formation, which then results in occlusion of the vein. Following this sequence of events, fibrous tissue forms and causes partial to complete obliteration of the vein, which may be temporary or permanent. An important role of this drug, as well as other sclerosing agents, is to control active hemorrhage and encourage hemostasis. This may be due to the esophageal and vascular smooth muscle spasm induced by the sclerosing agent.
During acute and active bleeding, the sodium tetradecyl sulfate injected directly into the esophageal varices may dissipate rapidly, as the varices have a much higher blood volume/flow rate and no functioning valves.
The mechanical compression effect of submucosal edema, created by the injection of sclerosing agents, may also be responsible for acute hemostasis.
- Primary indication
- Sotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small, uncomplicated varicose veins of the legs showing simple dilation, with competent valves.Curator reviewed · 2 structured indications
- Formula / weight
- C14H30O4S · 294.45 g/mol (avg)
- First approval
- United States, 2004
- Also known as
- Tetradecyl hydrogen sulfate
- Brand names
Resolves to
GROJOWHVXQYQGN-UHFFFAOYSA-NSMILESCCCCC(CC)CCC(CC(C)C)OS(O)(=O)=OWhat you can answer from here — as of July 08, 2025
Which drugs share a target with Tetradecyl hydrogen sulfate (ester), and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account